Navigation Links
NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
Date:9/4/2007

ming of completion of such trials; filings for regulatory approval in the United States and in the European Union and the timing of such filings as well as the scope of the indications that the Company is seeking approval for with respect to such filings; the potential markets for NGX-4010; the potential efficacy and benefits of NGX-4010; and NeurogesX' plans to commercialize NGX-4010, including with respect to sales force plans and plans to enter into commercial partnerships. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, subsequent analysis of data from NeurogesX' C117 trial may cause the results to be viewed less favorably as compared to NeurogesX' initial analysis of such trial's results; past results of clinical trials may not be indicative of future clinical trials results; NGX-4010 may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies and changing standards of care; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; NeurogesX' ability to obtain additional financing; NeurogesX' ability to obtain and maintain future commercial partnerships; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX, Inc.

Stephen Ghiglieri

(650) 508-2116

The Ruth Group

Investors / Med
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , August 27, 2014 ... Market By Products (Dental Radiology, CAD/CAM, Dental Chairs, Dental Lasers), Current ... by MarketsandMarkets, the global Dental Equipment Market is expected ... million in 2014, growing at a CAGR of ... 95 market data tables and 61 figures spread ...
(Date:8/27/2014)... Aug. 27, 2014 Pulse Systems, Inc. , ... Practice Management , and Revenue Cycle Management (RCM) ... practices performed by some RCM vendors, at UBM Medica,s ... on September 19-20, 2014.  A presenter ... in September with a new session encouraging practices to "Look ...
(Date:8/27/2014)... 2014 Sihuan Pharmaceutical Holdings Group Ltd. ... leading pharmaceutical company with the largest cardio-cerebral vascular ... prescription drug market, today announced the unaudited ... (collectively the "Group") for the six months ended ... HighlightsFor the Six months ended 30 JuneKey Income ...
Breaking Medicine Technology:Dental Equipment Market Worth $7,138.9 Million by 2019 2Dental Equipment Market Worth $7,138.9 Million by 2019 3Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 2Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 3Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 4Sihuan Pharmaceutical Announces 2014 Interim Results 2Sihuan Pharmaceutical Announces 2014 Interim Results 3Sihuan Pharmaceutical Announces 2014 Interim Results 4Sihuan Pharmaceutical Announces 2014 Interim Results 5Sihuan Pharmaceutical Announces 2014 Interim Results 6Sihuan Pharmaceutical Announces 2014 Interim Results 7
... 2012 Quest International, Inc., a leading global supplier ... announced today that is has contributed $5000 to the ... American Cancer Society Key Gala, that benefits the Boston ... on Thursday, March 29, 2012. "We are ...
... Access NOW! (PCPAN) coalition today applauded the United Mine Workers ... Express Scripts, Inc. (ESI) and Medco Health Solutions, two ... the Federal Trade Commission (FTC), the UMW said the ... union mine workers. UMW is a growing ...
Cached Medicine Technology:Quest International Donates $5000 to the American Cancer Society 2Nationwide Coalition Applauds United Mine Workers For Voicing Concern Over Proposed ESI/Medco Merger 2
(Date:8/27/2014)... WEDNESDAY, Aug. 27, 2014 (HealthDay News) -- A new ... an effective treatment for seniors with sleep apnea. ... obstructive sleep apnea, a condition in which the airway ... interrupted sleep that leads to daytime drowsiness. ... stream of air through a patient,s nose via a ...
(Date:8/27/2014)... from our parents shapes many aspects of our lives. ... epigenome that is set during development, but can be ... by those of our parents and grandparents. , The ... supporting proteins that determine whether genes are expressed or ... our own health, but also that it may be ...
(Date:8/27/2014)... Boston, MA (PRWEB) August 27, 2014 Tejal ... Patient Safety Foundation (NPSF) and the NPSF Lucian Leape ... announced in the August 25 issue of Modern Healthcare magazine. ... MD, PhD; and Andrew Sussman, MD, MBA; NPSF Lucian ... Gary Kaplan, MD, who is a member of both the ...
(Date:8/27/2014)... August 27, 2014 Scientists at The Scripps ... a specific signaling pathway can be associated with alcohol ... a gene, called neurofibromatosis type 1 (Nf1), which TSRI ... The new research shows Nf1 regulates gamma-aminobutyric acid (GABA), ... relaxation. , "This novel and seminal study provides ...
(Date:8/27/2014)... Georgia State University’s Center for Leadership in Disability ... the Maternal and Child Health Bureau of the ... of the Autism Plan for Georgia, aimed at ... spectrum disorder. , In preparing for this project, ... of key stakeholders from across Georgia. The resulting ...
Breaking Medicine News(10 mins):Health News:Sleep Apnea Treatment Helps Seniors, Study Finds 2Health News:Scientists map the 'editing marks' on fly, worm, human genomes 2Health News:Scientists map the 'editing marks' on fly, worm, human genomes 3Health News:Scientists map the 'editing marks' on fly, worm, human genomes 4Health News:NPSF President Among 100 Most Influential in Health Care 2Health News:NPSF President Among 100 Most Influential in Health Care 3Health News:Scripps Research Institute scientists link alcohol-dependence gene to neurotransmitter 2Health News:Center for Leadership in Disability Awarded $600,000 Grant to Improve Services for Georgia’s Children and Youth with Autism 2
... Adlyfe, a private company,developing novel diagnostic testing ... that it has appointed Roxanne Duan, Ph.D.,as Vice ... for overseeing,the Adlyfe,s Research efforts and will report ... to Adlyfe with nearly two decades of experience. ...
... 17 Symmetry Medical Inc.,(NYSE: SMA ), ... orthopedic,device industry and other medical markets, announced today ... http://www.symmetrymedical.com, which contains improved,user- friendly features. ... languages, provides easy to,find product information and a ...
... concludes, , , MONDAY, Sept. 17 (HealthDay News) -- ... asthma you develop, new research suggests. , The ... countries had more allergy-triggered asthma symptoms than did ... "The link between atopic sensitization and asthma symptoms ...
... YORK -- Before a new treatment becomes available, researchers ... in clinical research trials. But finding these patients is ... studies or unable to participate due do logistical hurdles. ... novel treatment approaches -- and beneficial new therapies take ...
... SAN DIEGO, Sept. 17 CryoCor, Inc. (Nasdaq:,CRYO), a ... announced today that Edward F. Brennan, President and Chief,Executive ... to present at the Maxim Group First Annual Growth ... at 10:00 a.m. ET at The Grand,Hyatt Hotel. ...
... address the nation,s largest public health challenges, including AIDS, should be ... ... plans, WASHINGTON, Sept. 17 ... next President to,commit to ending the AIDS epidemic in America. They ...
Cached Medicine News:Health News:Adlyfe Appoints Roxanne Duan as Vice President of Research 2Health News:Adlyfe Appoints Roxanne Duan as Vice President of Research 3Health News:Symmetry Medical Launches New Global Web site 2Health News:Symmetry Medical Launches New Global Web site 3Health News:Allergy-Induced Asthma More Common in Affluent Countries 2Health News:Allergy-Induced Asthma More Common in Affluent Countries 3Health News:IMPACT initiative looks to improve patient participation in clinical trials 2Health News:CryoCor to Present at Maxim Group First Annual Growth Conference in New York 2Health News:More Than 100 Organizations Call for a National AIDS Strategy to End the Epidemic in the United States 2Health News:More Than 100 Organizations Call for a National AIDS Strategy to End the Epidemic in the United States 3
... designed to give reliable performance for all mixing ... button, power supply socket and fuse holder are ... The speed knob is located on the bottom ... a minimum 950 rpm to a maximum of ...
ThermoPrep 3's two systems in "one" approach, its capability to accommodate up to two standard microplates and its user-selectable settings offers the versatility and throughput you need in today's l...
... only four-color, automated benchtop flow cytometry system ... sorting. Designed specifically to support a wide ... software instrument control, auto-sample loading, and push-button ... FACSCalibur is fully modular so it can ...
... cytometer especially suited for cell analysis ... CyFlow allows to analyze scatter signals ... fluorescence channels. Data acquisition, analysis, and ... built-in PC employing Partec DPAC software, ...
Medicine Products: